Skip to main content
Equibles
BMY logo

BMY · Bristol Myers Squibb Co · Documents

Track BMY — free

Use BMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$63.43 +1.11 (+1.78%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$129.66B
Shares
2.04B
Volume · Nov 13 9.27M Avg daily vol (3M) 10.87M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $48.19B down 0.2% 10-K filed Feb 11, 2026 Quarterly report FY2026 Q3 Revenue $13.07B up 6.9% 10-Q filed Oct 29, 2026 Latest results Revenue rose 7%; full-year outlook raised 8-K filed Oct 29, 2026 Earnings call Q3 2026 earnings call Held Oct 29, 2026
2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

BMS reported third-quarter 2026 revenue of $13,069 million, up 7%, and GAAP EPS of $1.05 versus $1.08; nine-month revenue was $37,532 million, up 5%, with GAAP EPS of $3.98 versus $2.93.

Revenue $13.07B ▲ 6.9% Net income $2.16B ▼ 1.8% Diluted EPS $1.05 ▼ 2.8%
Read from the MD&A section
Oct 29
Earnings call
Q3 2026 earnings call

Bristol-Myers Squibb reported third-quarter revenue of approximately $13.1 billion, up 7%, raised 2026 non-GAAP EPS guidance to $6.35 to $6.55, and posted growth portfolio revenue of $7.7 billion, up 12%.

Oct 29
Current report 8-K
Revenue rose 7%; full-year outlook raised

Third-quarter revenue increased 7% to $13.1 billion and Growth Portfolio revenue increased 12% to $7.7 billion. Bristol Myers Squibb raised 2026 revenue guidance to $49.75 billion to $50.25 billion and updated non-GAAP EPS to $6.35 to $6.55.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook Third quarter revenues increased 7% to $13.1 billion Growth Portfolio revenues increased 12% to $7.7 billion Raising 2026 revenue guidance to a range of $49.75 billion to $50.25 billion; Updating non-GAAP EPS range to $6.35 to $6.55, inclusive of a $(0.60) per share net impact from Acquired IPRD charges and licensing income Open the document at this passage
Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $12.97B ▲ 5.7% Net income $3.32B ▲ 153.2% Diluted EPS $1.62 ▲ 153.1%
Apr 30
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $11.49B ▲ 2.6% Net income $2.68B ▲ 9.0% Diluted EPS $1.31 ▲ 9.2%
Mar 25
Proxy statement DEF 14A Meeting May 5, 2026
Proxy statement AI summary on its way
Feb 11
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $48.19B ▼ 0.2% Net income $7.05B Diluted EPS $3.46
2025
Oct 30
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $12.22B ▲ 2.8% Net income $2.2B ▲ 81.8% Diluted EPS $1.08 ▲ 80.0%
Jul 31
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $12.27B ▲ 0.6% Net income $1.31B ▼ 22.0% Diluted EPS $0.64 ▼ 22.9%
Feb 12
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $48.3B ▲ 7.3% Net loss $8.95B Diluted EPS -$4.41
Showing 1–50 of 208 documents
Key facts CIK 14272 CUSIP 110122108 13F (30d) 2056 filings 1929 filers Visit website Investor relations